Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel
NASDAQ:XCUR

Exicure Q1 2025 Earnings Report

Exicure logo
$1.20 -0.02 (-1.23%)
Closing price 03:57 PM Eastern
Extended Trading
$1.21 +0.01 (+0.58%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Exicure EPS Results

Actual EPS
-$0.45
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Exicure Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Exicure Announcement Details

Quarter
Q1 2025
Date
6/27/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Exicure's next earnings date is estimated for Thursday, November 12, 2026, based on past reporting schedules.

Conference Call Resources

Exicure Earnings Headlines

Contrasting ProQR Therapeutics (NASDAQ:PRQR) & Exicure (NASDAQ:XCUR)
September 27 at 8:58 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31055597
Exicure Granted Extension By Nasdaq To Regain Compliance By Dec. '26
September 16, 2026  |  rttnews.comhttps://www.rttnews.com/3691538/exicure-granted-extension-by-nasdaq-to-regain-compliance-by-dec-26.aspx
Should You Convert a Traditional IRA to a Roth After 60?
Considering a Roth conversion after 60? The upside includes no income limits on conversions, potential tax-free qualified withdrawals, and no lifetime required minimum distributions. The catch: converting triggers ordinary income tax in the year you convert, and the decision cannot be reversed. The right move depends on your income, tax bracket, and retirement timeline.tc pixel
September 28 at 1:00 AM  |  SmartAsset (Ad)
Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement
September 16, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/exicure-receives-nasdaq-extension-regain-120000361.html
Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders' Equity Requirement
September 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/16/3363130/33289/en/exicure-receives-nasdaq-extension-to-regain-compliance-with-stockholders-equity-requirement.html
Exicure Announces Planned Issuance of Common Stock to Settle $1.0 Million Milestone Payment to GPCR Therapeutics
August 3, 2026  |  quiverquant.comQ
See More Exicure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Exicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Exicure and other key companies, straight to your email.

About Exicure

Exicure (NASDAQ:XCUR) was a biotechnology company focused on developing therapeutics based on its spherical nucleic acid (SNA) technology. The company’s platform was designed to deliver nucleic acids into cells and tissues, with the goal of regulating disease-related genes and proteins.

Exicure’s research programs addressed conditions in dermatology, immunology and other therapeutic areas. Its development portfolio included candidates such as AST-005, an SNA-based therapy investigated for psoriasis, along with programs targeting inflammatory and genetic diseases. The company’s work was primarily conducted through research and clinical-development activities rather than commercialized products.

Exicure was headquartered in the Chicago area and had operated as a publicly traded biotechnology company on Nasdaq under the symbol XCUR. Public information about its later operations, current leadership and active development programs is limited, and the company’s status has changed substantially since its earlier clinical-stage period.

View Exicure Profile
Earnings Tools